https://pharmaphorum.com/ en Fri, 18 Apr 2025 18:11:32 +0000 Fri, 18 Apr 2025 18:11:14 +0000 https://pharmaphorum.com/market-access/new-fda-head-says-no-more-pharma-advisory-committees The announcement signals a new administration attempting to distance itself from industry, but the actual impact seems small. Jonah.Comstock https://pharmaphorum.com/market-access/new-fda-head-says-no-more-pharma-advisory-committees 2025-04-18T18:11:14+0000 Feed - News and features https://pharmaphorum.com/news/gsk-cements-blenrep-comeback-mhra-approval GSK's Blenrep has nearly completed its winding road as the multiple myeloma drug receives approval for second-line us in the UK. Jonah.Comstock https://pharmaphorum.com/news/gsk-cements-blenrep-comeback-mhra-approval 2025-04-18T16:05:03+0000 Feed - News and features https://pharmaphorum.com/news/who-sans-us-finishes-draft-pandemic-preparedness-agreement The WHO has concluded negotiations on a 30-page draft agreement on pandemic preparedness. It goes before the assembly for consideration in May. Jonah.Comstock https://pharmaphorum.com/news/who-sans-us-finishes-draft-pandemic-preparedness-agreement 2025-04-18T15:08:24+0000 Feed - News and features https://pharmaphorum.com/news/merida-raises-121m-graves-drug-and-other-financings Our round-up of recent biotech financings includes rounds for Merida, Glycomine, Attovia, Imbria, and Solu Therapeutics. Phil.Taylor https://pharmaphorum.com/news/merida-raises-121m-graves-drug-and-other-financings 2025-04-18T08:28:26+0000 Feed - News and features https://pharmaphorum.com/news/lilly-soars-first-data-oral-obesity-candidate Shares in Eli Lilly rose sharply in pre-market trading today after it reported phase 3 results for oral diabetes and weight-loss drug orforglipron. Phil.Taylor https://pharmaphorum.com/news/lilly-soars-first-data-oral-obesity-candidate 2025-04-17T13:14:43+0000 Feed - News and features